 |
*Read Disclaimer Sponsored Content |
|
April 14, 2026 | Unsubscribe |
|
Hello! |
New Alert: Cardiol Therapeutics Inc. (NASDAQ: CRDL) |
CRDL is our new NASDAQ biotech alert. |
CRDL is trading under 2.00 - and the company is approaching what could be a major catalyst. |
CRDL is a NASDAQ listed “late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease”. |
The company's “lead small-molecule drug candidate, CardiolRx™, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure”. |
The Disease: A Debilitating & Underserved Cardiac Condition |
Pericarditis is the most common form of pericardial disease with a prevalence of 160,000 in the United States. |
The disease burden is substantial. |
According to a study published in the American College of Cardiology: |
"Up to 30% of the patients with acute pericarditis can have recurrent pericarditis, which can be remarkably difficult to treat, with treatment duration lasting up to 5-7 years in patients with multiple recurrences.”
|
The unmet need is just as striking. |
According to the Journal of the American Heart Association, the "disease burden is substantial and treatment options are currently inadequate" and "there are no US treatment guidelines for pericarditis or recurrent pericarditis". |
The economic toll is also significant. |
Studies show that "conventional treatments fail to provide adequate symptom control and prevention of future recurrences for many patients," with "sustained NSAIDs and systemic steroids complicated by serious side effects." |
This is precisely where CRDL steps in. |
The MAVERIC Program is evaluating CardiolRx™ for “the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations”. |
The program “comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing pivotal Phase III MAVERIC trial (NCT06708299).” |
The MAVERIC Phase III Trial: Approaching a Critical Milestone |
CRDL is now in the most important stage of its clinical journey. |
In January 2026, the company announced a key milestone: |
“Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis” |
Highlights: |
“Clinical trial infrastructure fully operational in the U.S. with more than 15 leading cardiovascular centers actively enrolling patients.” “Activation of additional top-tier clinical sites in Europe and Canada underway, further accelerating enrollment momentum.” “Full enrollment expected in Q2 2026.”
|
Critically, the MAVERIC Phase III trial is "fully funded through to a planned New Drug Application submission with the FDA." |
The FDA has already granted CRDL an important designation: “The U.S. FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, including recurrent pericarditis.” |
Orphan Drug Designation from the FDA comes with meaningful benefits - including eligibility for federal funding assistance, tax credits, and seven years of market exclusivity upon approval. |
ARCHER: Phase II Clinical Proof of Concept in Myocarditis |
Beyond pericarditis, CRDL has already delivered compelling Phase II clinical data in another serious heart disease: acute myocarditis. |
Acute myocarditis is "an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in individuals under 35 years of age.” |
There are currently "no FDA-approved drug therapies for acute myocarditis”. |
Patients hospitalized with the condition experience "an average seven-day length of stay and a 4 – 6% risk of in-hospital mortality, with average hospital charge per stay estimated at $110,000 in the United States". |
ARCHER was a “randomized, double-blind, placebo-controlled Phase II trial of CardiolRx™ in 109 patients with acute myocarditis at 34 sites across five countries”. |
The program “comprises the completed Phase II ARCHER study (NCT05180240), which evaluated the safety, tolerability, and efficacy of CardiolRx™ in this patient population.” |
Here are some of the company’s recent accomplishments: |
“In August 2025, the Company reported topline results from ARCHER. CardiolRx™ produced a significant reduction in left ventricular ("LV") mass (−9.2g; p=0.0117) and was shown to improve multiple pre-specified cardiac magnetic resonance imaging ("CMR") endpoints following 12 weeks of treatment, providing the first clinical evidence that CardiolRx™ can improve cardiac structure, heart size, recovery, and function in patients with inflammatory heart disease.”
“The magnitude of LV mass reduction observed in ARCHER is similar to that achieved with several commonly prescribed blockbuster drugs for heart failure, obesity, and hypertension-treatments proven to improve long-term survival and reduce major cardiac events.” “In November 2025, new and comprehensive data from ARCHER were presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases in Trieste, Italy. The presentation provided additional CMR endpoint data indicating that the meaningful structural improvement in the heart was the result of recovery from inflammation-driven edema. Consistent with prior clinical studies in inflammatory heart disease, CardiolRx™ was shown to be safe and well tolerated.” “Subsequent to year-end, in February 2026, the full ARCHER study results were published in ESC Heart Failure, a leading journal of the European Society of Cardiology, providing broader peer-reviewed dissemination of the clinical evidence to the international cardiology community.” “The ARCHER results provide additional support for the ongoing MAVERIC trial in recurrent pericarditis. Myocarditis and pericarditis are inflammatory diseases of the myocardium and pericardium, respectively, and are recognized to fall within the spectrum of inflammatory myopericardial syndrome, an umbrella term describing the potential myocarditis-pericarditis overlap: similar causes, anatomical contiguous structures, and mixed forms with possible reciprocal involvement, such as myopericarditis and perimyocarditis.”
|
CRD-38: A Next-Generation Drug Targeting Heart Failure |
CRDL is not a one-drug story. |
The company is also developing CRD-38, a “novel, subcutaneously administered drug formulation intended for the treatment of inflammatory heart disease, including heart failure”. |
Heart failure is “a leading cause of death and hospitalization in the developed world”. |
Sadly, it “affects more than 64 million people globally and associated healthcare costs exceed $30 billion annually in the U.S. alone”. |
Here are some of CRDL’s recent accomplishments: |
“Throughout 2025, the Company advanced IND-enabling studies and conducted activities necessary to support an IND application with the U.S. FDA and the initiation of a Phase I clinical program. This progress included formulation optimization, as well as the conduct of pharmacokinetic and toxicology studies.” “In February 2025, Cardiol announced the publication of research in the Journal of the American College of Cardiology: Basic to Translational Science demonstrating that subcutaneously administered cannabidiol provides cardioprotection in a heart failure model by improving cardiac function and reducing hypertrophy, remodelling, inflammation, and cell death through preservation of mitochondrial function.”
|
Intellectual Property Protected to 2040 |
In November 2025, CRDL “received a U.S. patent allowance broadly protecting its heart drugs, including CardiolRx™ and CRD-38, for use in the treatment or prevention of an extensive range of cardiac conditions, including heart failure, myocarditis, acute pericarditis, inflammatory cardiomyopathy, cardiac toxicity from anti-cancer therapies, and atherosclerosis, to October 2040”. |
Plus, “the patent allowance covers new areas of heart disease, including those identified for potential research expansion based on the ARCHER findings, adding extensive intellectual property protection to the Company's product portfolio”. |
The company noted the allowance also "fortifies Cardiol’s global intellectual property portfolio, adding to granted and pending patent applications in Europe, Japan, Canada, Australia, and China”. |
In 2025, CRDL strengthened its Board of Directors with the election of Dr. Timothy Garnett - the former Chief Medical Officer of Eli Lilly and Company, one of the world's largest pharmaceutical companies. |
Furthermore, CRDL recently “Raised aggregate gross proceeds of $31 million providing a cash runway into Q4 2027. |
Most recently, in April, the company announced: |
“Cardiol Therapeutics Announces Year-End 2025 Update on Operations” |
Here are some of the comments from this press release: |
"2025 was a pivotal year of clinical execution and strategic advancement for Cardiol. We initiated our Phase III MAVERIC trial in recurrent pericarditis, reported positive Phase II ARCHER data demonstrating that CardiolRx™ improves the underlying biology of inflammatory heart disease and reduces inflammation-driven structural damage, and strengthened our balance sheet to support key value-inflection milestones," said David Elsley, President and Chief Executive Officer of Cardiol Therapeutics. |
|
|
In addition: |
"We are now fully funded through completion of the MAVERIC trial, which is designed to support a New Drug Application submission for CardiolRx™ in the prevention of recurrent pericarditis-an expanding market with a significant unmet need for a safe, accessible, non-immunosuppressive oral therapy. In parallel, the positive ARCHER results-our second successful Phase II study in inflammatory heart disease-along with continued expansion of our patent portfolio in the United States and advancement of CRD-38 toward IND submission, further strengthen our product pipeline. We thank our clinical collaborators and the patients whose participation has enabled this progress." |
|
|
We believe CRDL could be positioned for high growth. |
Make sure to do your own due diligence. |
Sources: ACC, JAHA, Springer, FDA, PR1, PR2, PR3, PR4, PR5, PR6, PR7, PR8, PR9, Website, Chart |
|
Happy Trading! |
|
AwesomeStocks Team |
|
Note: We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose. |
|
|
DISCLAIMER: |
You should read and understand this disclaimer in its entirety before joining the website or email/blog list of AwesomeStocks.com (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help. |
The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at www.sec.gov; the Financial Industry Regulatory Authority (the "FINRA") at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete. |
The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete. |
Owners and operators of the Publisher have been compensated nine thousand dollars by bank wire transfer on 4/10/26 for the distribution of this advertisement about CRDL dated 4/14/26. The Publisher and its owners and operators hold no stocks or bonds in companies discussed in the Advertisement. Owners and operators of the Publisher own several newsletters, therefore you may receive multiple publications and emails featuring companies at different or the same time. |
You are receiving this report/release because you subscribed to receive it at our website or through a third-party site. All our newsletters include an "unsubscribe" link, and you can remove yourself at any time from our newsletters by clicking on that "unsubscribe" link. You can also contact us at info@AwesomeStocks.com to change your information at any time. By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link: |
www.AwesomeStocks.com/Disclaimer and www.AwesomeStocks.com/Privacy-Policy |
By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink. |
